ISRCTN14296856进行中（未招募）2 期
A randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of oral BT-11 in mild to moderate ulcerative colitis
andos Biopharma Inc.0 个研究点目标入组 195 人开始时间: 2019年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects aged 18 to 65 years, inclusive
- •2. Diagnosis of UC for at least 3 months before screening
- •3. Mild to moderate UC, as defined by a total Mayo Score of 4 to 10 inclusive at baseline with an MES 2 (confirmed by the central reader)
- •4. If subjects have previously received biologic therapy for UC (i.e., tumor necrosis factor [TNF] antagonists, vedolizumab or ustekinumab), they must have a washout period of 8 weeks before randomization
- •5. If subjects are receiving the following UC treatments, they must be on a stable dose for at least I month before randomization: 5- aminosalicylates (5-ASAs), oral corticosteroids
- •6. If subjects are receiving bile-salt sequestrant, they must be on a stable dose for at least 3 months before randomization
- •7. If subjects are receiving any non-prohibited medications, they must agree to maintain stable doses of concomitant medication s for UC for the duration of the trial
- •8. Unlikely to conceive, as defined by 1 of the following: (a) subject is surgically sterilized female, (b) subject is postmenopausal female 2: 45 years of age with clinical documentation of menopause (i.e., 12 months without menses), or c) matter is male or subject is woman of childbearing potential (WOCBP), and agrees to abstain from heterosexual activity, use adequate hormonal contraception, or use double barrier contraception
- •9. For WOCBP, the subject must have a negative pregnancy test at screening and within 24 hours before the first dose of study drug.
- •10. Able to participate fully in all aspects of this clinical trial
- •11. Written informed consent must be obtained and documented
排除标准
- •1. A diagnosis of CD, indeterminate colitis, or presence or history of the fistula with CD
- •2. Severe UC as per modified Truelove and Witts criteria
- •3. Disease activity limited to the distal 15 cm (proctitis)
- •4. Treatment with an immunosuppressant (azathioprine, 6- mercaptopurine [6-MP]) within 25 days before randomization
- •5. History of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma; history or is at imminent risk of colectomy
- •6. History or current evidence of colonic dysplasia or adenomatous colonic polyps
- •7. Current bacterial or parasitic pathogenic enteric infection, including Clostridium difficile, known infection with hepatitis B or C virus, known infection with human immunodeficiency virus, infection requiring hospitalization or intravenous s antimicrobial therapy, or opportunistic infection within 6 months prior to screening, any infection requiring antimicrobial therapy within 2 weeks prior to screening, history of more than 1 episode of herpes zoster or any episode of disseminated zoster
- •8. Live virus vaccination within 1 month prior to screening
- •9. Treatment with cyclosporine, mycophenolate, tacrolimus, or tofacitinib within 4 weeks prior to randomization
- •10. Treatment with intravenous corticosteroids, rectal corticosteroids, or rectal 5-ASA within 2 weeks before randomization
- •11. Fecal microbiota transplantation within 1 month prior to screening
- •12. A concurrent clinically significant, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, Gl, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results or poses additional risk to the subject
- •13. Known primary or secondary immunodeficiency
- •14. History of myocardial infarction, unstable angina, transient ischemic attack, decompensated heart failure requiring hospitalization, congestive heart failure (New York Health Association [NYHA] Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening
- •15. Laboratory abnormalities at screening, as determined and documented by the investigator
- •16. Pregnant or lactating females
- •17. Any surgical procedure anesthesia within I month prior to screening, or planned elective surgery during the study
- •18. History of malignant neoplasms or carcinoma in situ within 5 years prior to screening
- •19. Current or recent history of alcohol dependence or illicit drug use that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
- •20. Mental or legal incapacitation at the time of screening visit or a history of clinically significant psychiatric disorders that would impact the ability to participate in the trial according to the investigator
- •21. Unable to attend study visits or comply with procedures
- •22. Concurrent participation in any other interventional study
- •23. Received any investigational therapy within 30 days of initiation of study drug
- •24. Underlying severe dise
研究者
相似试验
招募中
1 期
A study to test trimodulin in adult hospitalized patients with severe pneumoniaCTIS2022-501352-28-00BIOTEST AG569
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.EUCTR2022-000736-37-BEBiotest AG390
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind, multicentre, multiple dose, cohort study with escalating doses to evaluate the safety and efficacy of the humanized monoclonal antibody (mab) BT061 administered subcutaneously or intravenously as 8 repeated doses to patients with moderate to severe chronic plaque psoriasis.patients with moderate to severe chronic plaque psoriasisMedDRA version: 12.0Level: LLTClassification code 10037153Term: PsoriasisMedDRA version: 12.0Level: PTClassification code 10037153Term: PsoriasisEUCTR2008-007458-37-HUBiotest AG
招募中
1 期
A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia.on-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)MedDRA version: 20.1Level: LLTClassification code: 10010120Term: Community acquired pneumonia Class: 10021881MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862CTIS2024-513002-60-00Biotest AG390
进行中（未招募）
1 期
This study is being conducted to evaluate efficacy and safety of Octreotide compared with Placebo via subcutaneous depot route in subjects with polycystic liver diseasePolycystic liver diseaseEUCTR2021-003764-27-NLCamurus AB69